SCHEMBL3379840

SCHEMBL3379840

Cc1cc(NS(C)(=O)=O)ccc1-c1ccc(F)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNIK Q9UKE5 1/20 0.54
CYP17A1 P05093 4/20 0.53
KIT P10721 2/20 0.49
MAP2K4 P45985 1/20 0.46
IKBKB O14920 1/20 0.46
CHUK O15111 1/20 0.46
CYP1A2 P05177 2/20 0.45
CYP3A4 P08684 2/20 0.45
CYP2D6 P10635 2/20 0.45
TSHR P16473 2/20 0.45
ALDH1A1 P00352 1/20 0.45
ALOX15 P16050 1/20 0.45
HSD17B10 Q99714 1/20 0.45
CLK4 Q9HAZ1 1/20 0.45
NR3C1 P04150 1/20 0.45
AR P10275 1/20 0.45
KIF11 P52732 2/20 0.44
PTGS2 P35354 3/20 0.44
MEN1 O00255 1/20 0.44
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4661111 0.87 CYP17A1 (0.56) CYP17A1IKBKBCHUKALDH1A1KIF11
SCHEMBL3377747 0.85 GLO1 (0.49) TNIKCYP17A1KITNR3C1AR
SCHEMBL4662605 0.84 KIF11 (0.68) CYP17A1KIF11MAPT
SCHEMBL3378764 0.83 PTGS2 (0.51) TNIKCYP17A1KITMAP2K4CYP1A2
SCHEMBL3378146 0.81 CYP17A1 (0.54) CYP17A1KIF11PTGS2HPGDMAPK1
Lithium SCHEMBL31041157 0.81 CYP17A1 (0.63) CYP17A1ALDH1A1KIF11LMNAHPGD
SCHEMBL3375960 0.81 CYP17A1 (0.56) CYP17A1KITNR3C1
SCHEMBL7833236 0.81 CYP17A1 (0.53) CYP17A1IKBKBCHUKALDH1A1HPGD
SCHEMBL4659812 0.79 KIF11 (0.66) KITMAP2K4ALDH1A1KIF11PTGS2
SCHEMBL6099629 0.79 POLB (0.56) CYP17A1HSD17B10CLK4PTGS2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US claimed
WO-2010056527-A2 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-20 WO claimed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US claimed
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US disclosed
WO-2010056527-A2 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-20 WO disclosed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, HCN4, KCNH2 TNIK 1504/4885CYP17A1 3984/4885KIT 4087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.